Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 243 results:
Συντάκτης [ Τίτλος(Desc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Karagiannis, Asterios  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Katsiki, N., Athyros V. G., Karagiannis A., Wierzbicki A. S., & Mikhailidis D. P. (2014).  Should we expand the concept of coronary heart disease equivalents?. Curr Opin Cardiol. 29(4), 389-95.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial.. J Hepatol. 57(2), 476.
Patoulias, D., Manafis A., Mitas C., Avranas K., Lales G., Zografou I., et al. (2018).  Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice.. Cardiovasc Hematol Disord Drug Targets. 18(2), 139-146.
Karagiannis, A., Tziomalos K., Papageorgiou A., Kakafika A. I., Pagourelias E. D., Anagnostis P., et al. (2008).  Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.. Expert Opin Pharmacother. 9(4), 509-15.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Stage of chronic kidney disease and severity of coronary heart disease manifestation.. Expert Opin Pharmacother. 13(4), 457-60.
Athyros, V. G., Tziomalos K., Florentin M., Karagiannis A., & Mikhailidis D. P. (2010).  Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. Curr Med Res Opin. 26(4), 839-42.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Statin-fibrate combination for mixed dyslipidaemia: a limited option?. Curr Med Res Opin. 26(9), 2137-40.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Pagourelias E. D., Savvatianos S. D., Elisaf M., et al. (2007).  Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients.. Open Cardiovasc Med J. 1, 8-14.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.. Curr Vasc Pharmacol. 7(3), 264-6.
Athyros, V. G., Karagiannis A., & Mikhailidis D. P. (2010).  Statins and heart failure.. J Am Coll Cardiol. 55(15), 1644-5; author reply 1646.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Statins and nonalcoholic fatty liver disease: a bright future?. Expert Opin Investig Drugs. 22(9), 1089-93.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and non-alcoholic steatohepatitis.. J Hepatol. 64(1), 241-2.
Athyros, V. G., Kakafika A., Karagiannis A., & Mikhailidis D. P. (2007).  Statins and regression of coronary atherosclerosis.. JAMA. 297(20), 2197; author reply 2197.
Athyros, V. G., Karagiannis A., Kakafika A., Elisaf M., & Mikhailidis D. P. (2007).  Statins and renal function. Is the compound and dose making a difference?. Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and Type 2 Diabetes Mellitus: An Update After 1 Year.. Curr Pharm Des. 22(18), 2723-5.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. Expert Opin Pharmacother. 16(10), 1449-61.
Paraskevas, K. I., Athyros V. G., Briana D. D., Kakafika A. I., Karagiannis A., & Mikhailidis D. P. (2007).  Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures.. Curr Drug Targets. 8(8), 942-51.
Athyros, V. G., Kakafika A. I., Tziomalos K., Papageorgiou A. A., & Karagiannis A. (2008).  Statins for the prevention of first or recurrent stroke.. Curr Vasc Pharmacol. 6(2), 124-33.
Anagnostis, P., Karras S. N., Athyros V. G., Mikhailidis D. P., & Karagiannis A. (2014).  Subclinical Cushing's syndrome and cardiovascular disease.. Lancet Diabetes Endocrinol. 2(5), 361.
Stavropoulos, K., Imprialos K. P., Doumas M., Athyros V. G., & Karagiannis A. (2018).  Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?. J Hypertens. 36(3), 701.
T
Polyzos, S. A., Perakakis N., Boutari C., Kountouras J., Ghaly W., Anastasilakis A. D., et al. (2019).  Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD.. J Clin Endocrinol Metab.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?. Curr Vasc Pharmacol. 14(1), 88-97.
Athyros, V. G., Mikhailidis D. P., Papageorgiou A. A., Didangelos T. P., Peletidou A., Kleta D., et al. (2005).  Targeting vascular risk in patients with metabolic syndrome but without diabetes.. Metabolism. 54(8), 1065-74.
Kostapanos, M. S., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Therapeutic options for statin-intolerant patients.. Curr Med Res Opin. 28(3), 345-9.
Mitsiou, E. K., Athyros V. G., Karagiannis A., & Mikhailidis D. I. (2012).  Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?. Open Cardiovasc Med J. 6, 28-32.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές